Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPELINE-RSV-F: Prevention of RSV Infection in Infants
NCT07232706Phase 3Recruiting
- Sponsor
- Centre Hospitalier Annecy Genevois
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Centre Hospitalier Annecy Genevois. Started May 2026; status: recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07232706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232706.